152 related articles for article (PubMed ID: 37831397)
1. Economic Evaluation of Rotavirus Vaccination in Children Aged Under Five Years in South Africa.
Mohy A; Page N; Boyce W; Gomez JA
Clin Drug Investig; 2023 Nov; 43(11):851-863. PubMed ID: 37831397
[TBL] [Abstract][Full Text] [Related]
2. Cost-effectiveness analysis measuring the total costs against the health benefits of three different rotavirus vaccines for Mexico.
Gomez J; Velázquez FR; Guzman-Holst A; Cervantes Apolinar MY; Van Bellinghen LA; Van Vlaenderen I; van Oorschot D
Hum Vaccin Immunother; 2023 Aug; 19(2):2219189. PubMed ID: 37339232
[TBL] [Abstract][Full Text] [Related]
3. Health economic evaluation of 2-dose and 3-dose rotavirus vaccines in children below 5 years of age in Morocco.
Mohy A; Lagoubi Y; Gomez JA; Amadou B; Bouskraoui M
Hum Vaccin Immunother; 2024 Dec; 20(1):2353480. PubMed ID: 38757507
[TBL] [Abstract][Full Text] [Related]
4. Cost-effectiveness analysis of the implementation of a National Immunization Program for rotavirus vaccination in a country with a low rotavirus gastroenteritis-related mortality: A South Korean study.
Lee H; Park SY; Clark A; Debellut F; Pecenka C; Kim DS; Kim HM; Kim JH; Cho H; Kim AY; Lee M; Jung SY; Seong BL; Kang HY
Vaccine; 2019 Aug; 37(35):4987-4995. PubMed ID: 31326252
[TBL] [Abstract][Full Text] [Related]
5. Burden of paediatric Rotavirus Gastroenteritis (RVGE) and potential benefits of a universal Rotavirus vaccination programme with a pentavalent vaccine in Spain.
Diez-Domingo J; Suriñach NL; Alcalde NM; Betegón L; Largeron N; Trichard M
BMC Public Health; 2010 Aug; 10():469. PubMed ID: 20698958
[TBL] [Abstract][Full Text] [Related]
6. Cost-effectiveness of rotavirus vaccination in the Philippines: A modeling study.
Villanueva-Uy MET; Lam HY; Aldaba JG; Uy TMZ; Valverde HA; Silva MWT; Mooney J; Clark A; Pecenka C
Vaccine; 2021 Nov; 39(48):7091-7100. PubMed ID: 34753614
[TBL] [Abstract][Full Text] [Related]
7. Cost effectiveness of a pentavalent rotavirus vaccine in Oman.
Al Awaidy ST; Gebremeskel BG; Al Obeidani I; Al Baqlani S; Haddadin W; O'Brien MA
BMC Infect Dis; 2014 Jun; 14():334. PubMed ID: 24941946
[TBL] [Abstract][Full Text] [Related]
8. Cost-effectiveness analysis of rotavirus vaccination in Argentina.
Urueña A; Pippo T; Betelu MS; Virgilio F; Hernández L; Giglio N; Gentile Á; Diosque M; Vizzotti C
Vaccine; 2015 May; 33 Suppl 1():A126-34. PubMed ID: 25919152
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and immunogenicity of two or three dose rotavirus-vaccine regimen in South African children over two consecutive rotavirus-seasons: a randomized, double-blind, placebo-controlled trial.
Madhi SA; Kirsten M; Louw C; Bos P; Aspinall S; Bouckenooghe A; Neuzil KM; Steele AD
Vaccine; 2012 Apr; 30 Suppl 1():A44-51. PubMed ID: 22520136
[TBL] [Abstract][Full Text] [Related]
10. A Phase III open-label, randomized, active controlled clinical study to assess safety, immunogenicity and lot-to-lot consistency of a bovine-human reassortant pentavalent rotavirus vaccine in Indian infants.
Rathi N; Desai S; Kawade A; Venkatramanan P; Kundu R; Lalwani SK; Dubey AP; Venkateswara Rao J; Narayanappa D; Ghildiyal R; Gogtay N; Venugopal P; Palkar S; Munshi R; Kang G; Babji S; Bavdekar A; Juvekar S; Ganguly N; Niyogi P; Ghosh Uttam K; Rajani HS; Kondekar A; Kumbhar D; Mohanlal S; Agarwal MC; Shetty P; Antony K; Gunale B; Dharmadhikari A; Tang Y; Kulkarni PS; Flores J
Vaccine; 2018 Dec; 36(52):7943-7949. PubMed ID: 30420116
[TBL] [Abstract][Full Text] [Related]
11. Cost-effectiveness of rotavirus vaccination in Albania.
Ahmeti A; Preza I; Simaku A; Nelaj E; Clark AD; Felix Garcia AG; Lara C; Hoestlandt C; Blau J; Bino S
Vaccine; 2015 May; 33 Suppl 1():A201-8. PubMed ID: 25919162
[TBL] [Abstract][Full Text] [Related]
12. Non-interference of Bovine-Human reassortant pentavalent rotavirus vaccine ROTASIIL® with the immunogenicity of infant vaccines in comparison with a licensed rotavirus vaccine.
Desai S; Rathi N; Kawade A; Venkatramanan P; Kundu R; Lalwani SK; Dubey AP; Venkateswara Rao J; Narayanappa D; Ghildiyal R; Gogtay NJ; Venugopal P; Palkar S; Munshi R; Bavdekar A; Juvekar S; Ganguly N; Niyogi P; Uttam KG; Kondekar A; Kumbhar D; Mohanlal S; Agarwal MC; Shetty P; Antony K; Gunale B; Dharmadhikari A; Deshpande J; Nalavade U; Sharma D; Bansal A; Tang Y; Flores J; Kulkarni PS
Vaccine; 2018 Sep; 36(37):5519-5523. PubMed ID: 30104114
[TBL] [Abstract][Full Text] [Related]
13. Cost-effectiveness of a new rotavirus vaccination program in Pakistan: a decision tree model.
Patel HD; Roberts ET; Constenla DO
Vaccine; 2013 Dec; 31(51):6072-8. PubMed ID: 24176497
[TBL] [Abstract][Full Text] [Related]
14. Cost-effectiveness analysis of vaccination against rotavirus with RIX4414 in France.
Standaert B; Parez N; Tehard B; Colin X; Detournay B
Appl Health Econ Health Policy; 2008; 6(4):199-216. PubMed ID: 19382820
[TBL] [Abstract][Full Text] [Related]
15. Burden of paediatric rotavirus gastroenteritis and potential benefits of a universal rotavirus vaccination programme with RotaTeq in France.
Huet F; Largeron N; Trichard M; Miadi-Fargier H; Jasso-Mosqueda G
Vaccine; 2007 Aug; 25(34):6348-58. PubMed ID: 17629598
[TBL] [Abstract][Full Text] [Related]
16. Effects of geographic and economic heterogeneity on the burden of rotavirus diarrhea and the impact and cost-effectiveness of vaccination in Nigeria.
Anderson JD; Pecenka CJ; Bagamian KH; Rheingans RD
PLoS One; 2020; 15(5):e0232941. PubMed ID: 32469927
[TBL] [Abstract][Full Text] [Related]
17. Cost-effectiveness of universal rotavirus vaccination in reducing rotavirus gastroenteritis in Ireland.
Tilson L; Jit M; Schmitz S; Walsh C; Garvey P; McKeown P; Barry M
Vaccine; 2011 Oct; 29(43):7463-73. PubMed ID: 21821085
[TBL] [Abstract][Full Text] [Related]
18. Cost-Effectiveness of Monovalent Rotavirus Vaccination of Infants in Malawi: A Postintroduction Analysis Using Individual Patient-Level Costing Data.
Bar-Zeev N; Tate JE; Pecenka C; Chikafa J; Mvula H; Wachepa R; Mwansambo C; Mhango T; Chirwa G; Crampin AC; Parashar UD; Costello A; Heyderman RS; French N; Atherly D; Cunliffe NA;
Clin Infect Dis; 2016 May; 62 Suppl 2(Suppl 2):S220-8. PubMed ID: 27059360
[TBL] [Abstract][Full Text] [Related]
19. Cost-effectiveness of a pentavalent human-bovine reassortant rotavirus vaccine for children ≤5 years of age in Taiwan.
Itzler RF; Chen PY; Lac C; El Khoury AC; Cook JR
J Med Econ; 2011; 14(6):748-58. PubMed ID: 21919673
[TBL] [Abstract][Full Text] [Related]
20. Effectiveness and cost-effectiveness of pediatric rotavirus vaccination in British Columbia: a model-based evaluation.
Fisman DN; Chan CH; Lowcock E; Naus M; Lee V
Vaccine; 2012 Dec; 30(52):7601-7. PubMed ID: 23107595
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
